| The reason why |  |
| The principle | |
| Examples from the lab | |
| What is important? | |
| The advantages | |
Individualized chemotherapy planning requires clinical experience.
Essential for a successful chemosensitivity test is not only a valid lab technique. The individual choice of the regimen to be tested and the transfer of lab results into clinical decisions-making processes is at least equally important. This makes high clinical competence concerning chemotherapy of tumor patients indispensable.
L.a.n.c.e. offers both. Our clinical directors are not only scientists of international format, but also renowned tumor specialists in their respective fields with long lasting clinical experience acquired at University hospitals.
Christian Kurbacher, MD, Ph.D.
Professor Uwe Reinhold, MD, Ph.D.
Ralf Reichelt, Ph.D.
Christian Kurbacher, MD, Ph.D. |
Founding member of L.a.n.c.e.; since 1994 specialist for gynecology and obstetrics; until 2003 head of the Division of Gynecologic Oncology at the Department of Gynecology and Obstetrics, Faculty of Medicine, University of Cologne; since 1985 scientific work in the field of chemosensitivity testing; |
| since 1993 internationally leading position in the clinical development of the ATP-TCA; project leader of numerous experimental and clinical studies on chemotherapy of malignant gynecological diseases. Member of numerous national and international associations such as the American Society of Clinical Oncology, the European Organization of Research and Treatment of Cancer, the European Association of Cancer Research, the International Society of Chemosensitivity Testing in Oncology, the German Cancer Association and the German Association for Gynecology and Obstetrics. Member of the organ commissions ‘ovary’ and ‘uterus malignoma’ of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) of the German Cancer Association. | |
Professor Uwe Reinhold, MD, Ph.D.
 |
Founding member of L.a.n.c.e.; since 1992 specialist for dermatology; until 2002 head doctor and vice dean of the Department of Dermatology at Bonn and Homburg/Saar University Hospital; since 1987 scientific and clinical work in the field of dermatological oncology; laureate of the German Skin Cancer award 2001; |
| project leader of numerous scientific projects in the field of diagnostics and treatment of skin cancer diseases (molecular diagnostics, tumor chemosensitivity testing); member of numerous national and international associations; board member of the Dermatological Cooperative Oncology Group (DeCOG) of the German Cancer Association (DKG). | |
 |
CEO of the L.a.n.c.e. Inc. – Master’s degree in biology; dissertation at the Department of Human Genetics at Bonn University in 1990; since 1990 involved in different oncological research projects in the pharmaceutical industry;since 1998 proxy and head of business development at megapharm GmbH, Sankt Augustin. Since 2003 he combines this function with the startup of L.a.n.c.e. as founding CEO. |
© 2004 | L.a.n.c.e. | Laboratory for Applied Neoplasia Research and Cytostatics Evaluation Inc. | powered by webunit.com